A prospective 4-year naturalistic follow-up of treatment and outcome of 300 bipolar I and II patients

Journal of Clinical Psychiatry

Volumn 75, Issue 3, 2014, Pages 254-263

  Simhandl, Christian ^a   Konig, Barbara ^a   Amann, Benedikt L ^a  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; LAMOTRIGINE; LITHIUM; LITHIUM CARBONATE; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID;

ADULT; ARTICLE; AUSTRIA; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MONOTHERAPY; NATURALISTIC INQUIRY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; RELAPSE;

ADULT; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LITHIUM; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84898753546     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13m08601     Document Type: Article

References (42)

1. Fagiolini A, Forgione R, Maccari M, et al. Prevalence, chronicity, burden and borders of bipolar disorder. J Affect Disord. 2013;18(2-3):161-169.
2. Fountoulakis KN, Kasper S, Andreassen O, et al. Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. EurArch Psychiatry Clin Neurosci. 2012;262 (suppl 1):l-48.
3. Miklowitz DJ, Scott J. Psychosocial treatments for bipolar disorder: cost-effectiveness, mediating mechanisms, and future directions. Bipolar Disord. 2009;11(suppl2):110-122.
4. Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2006;163(2): 217-224.
5. Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010; 67(1):26-36.
6. Harrow M, Goldberg JF, Grossman LS, et al. Outcome in manic disorders: a naturalistic fo11ow-up study. Arch Gen Psychiatry. 1990;47(7):665-671.
7. Winokur G, Coryell W, Akiskal HS, et al. Manic-depressive (bipolar) disorder: the course in light of a prospective ten-year fo11ow-up of 131 patients. Acta Psychiatr Scand. 1994;89(2):102-110.
8. Strober M, Schmidt-Lackner S, Freeman R, et al. Recovery and relapse in adolescents with bipolar affective illness: a five-year naturalistic, prospective fo11ow-up. JAm Acad Child Adoksc Psychiatry. 1995;34(6):724-731.
9. Coryell W, Turvey C, Endicott J, et al. Bipolar I affective disorder: predictors of outcome after 15 years. J Affect Disord. 1998;50(2-3):109-116.
10. Dittmann S, Biedermann NC, Grunze H, et al. The Stanley Foundation Bipolar Network: results of the naturalistic fo11ow-up study after 2.5 years of fo11ow-up in the German centres. Neuropsychobiology. 2002;46(suppl 1): 2-9.
11. Nolen WA, Luckenbaugh DA, Altshuler LL, et al. Correlates of 1-year prospective outcome in bipolar disorder: results from the Stanley Foundation Bipolar Network. Am J Psychiatry. 2004;161 (8): 1447-1454.
12. Azorin JM, Aubrun E, Bertsch J, et al. Mixed states vs pure mania in the French sample of the EMBLEM study: results at baseline and 24 months-European Mania in Bipolar Longitudinal Evaluation of Medication. BMC Psychiatry. 2009;9(1):33.
13. Haro JM, Reed C, Gonzalez-Pinto A, et al; EMBLEM Advisory Board. 2-Year course of bipolar disorder type I patients in outpatient care: factors associated with remission and functional recovery. Eur Neuropsychopharmacol. 2011;21(4):287-293.
14. Gonzalez-Pinto A, Barbeito S, Alonso M, et al. Poor long-term prognosis in mixed bipolar patients: 10-year outcomes in the Vitoria prospective naturalistic study in Spain. Clin Psychiatry. 2011;72(5):671-676.
15. Bowden CL, Perlis RH, Thase ME, et al. Aims and results of the NIMH Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). CNSNeurosci Ther. 2012;18(3):243-249.
16. Montoya A, Tohen M, Vieta E, et al. Functioning and symptomatic outcomes in patients with bipolar I disorder in syndromal remission: a 1-year, prospective, observational cohort study. J Affect Disord. 2010; 127(1-3):50-57.
17. Sagman D, Lee B, Chandresena R, et al. A Canadian naturalistic study of a community-based cohort treated for bipolar disorder. BMC Psychiatry. 2010;10(1):24.
18. Kessing LV, Hansen MG, Andersen PK, et al. The predictive effect of episodes on the risk of recurrence in depressive and bipolar disorders: a life-long perspective. Acta Psychiatr Scand. 2004;109(5):339-344.
19. Angst J, Gamma A, Sellaro R, et al. Recurrence of bipolar disorders and major depression: a life-long perspective. Eur Arch Psychiatry Clin Neurosci. 2003;253(5):236-240.
20. Angst J, Sellaro R. Historical perspectives and natural history of bipolar disorder. Biol Psychiatry. 2000;48(6):445-457.
21. Markar HR, Mander AJ. Efficacy of lithium prophylaxis in clinical practice. Br J Psychiatry. 1989;155(4):496-500.
22. Goldberg JF, Harrow M, Leon AC. Lithium treatment of bipolar affective disorders under naturalistic fo11owup conditions. Psychopharmacol Bu11. 1996;32(1):47-54.
23. Coryell W, Winokur G, Solomon D, et al. Lithium and recurrence in a long-term fo11ow-up of bipolar affective disorder. Psychol Med. 1997; 27(2):281-289.
24. Maj M, Pirozzi R, Magliano L, et al. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry. 1998;155(1):30-35.
25. Maj M, Pirozzi R, Bartoli L, et al. Long-term outcome of lithium prophylaxis in bipolar disorder with mood-incongruent psychotic features: a prospective study. J Affect Disord. 2002;71(1-3):195-198.
26. Biel MG, Peselow E, Mulcare L, et al. Continuation versus discontinuation of lithium in recurrent bipolar illness: a naturalistic study. Bipolar Disord. 2007;9(5):435-442.
27. Nierenberg AA, Friedman ES, Bowden CL, et al. Lithium Treatment Moderate-Dose Use Study (LiTMUS) for bipolar disorder: a randomized comparative effectiveness trial of optimized personalized treatment with and without lithium. Am J Psychiatry. 2013;170(1):102-110.
28. Licht RW, Vestergaard P, Rasmussen NA, et al. A lithium clinic for bipolar patients: 2-year outcome of the first 148 patients. Acta Psychiatr Scand. 2001;104(5):387-390.
29. Silverstone T, McPherson H, Hunt N, et al. How effective is lithium in the prevention of relapse in bipolar disorder? a prospective naturalistic fo11ow-up study. Aust NZJ Psychiatry. 1998;32(1):61-66.
30. Wilting I, Heerdink ER, Mersch PP, et al. Association between lithium serum level, mood state, and patient-reported adverse drug reactions during long-term lithium treatment: a naturalistic fo11ow-up study. Bipolar Disord. 2009;11(4):434-440.
31. Altamura AC, Mundo E, Dell'Osso B, et al. Quetiapine and classical mood stabilizers in the long-term treatment of bipolar disorder: a 4-year fo11ow-up naturalistic study. J Affect Disord. 2008;110(1-2):135-141.
32. Kulkarni J, Filia S, Berk L, et al. Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice. BMC Psychiatry. 2012; 12(1):228.
33. Born C, Seitz NN, Grunze H, et al. Preliminary results of a fine-grain analysis of mood swings and treatment modalities of bipolar I and II patients using the daily prospective life-chart-methodology. Acta Psychiatr Scand. 2009; 120(6):474-480.
34. Post RM, Altshuler LL, Frye MA, et al. Complexity of pharmacologic treatment required for sustained improvement in outpatients with bipolar disorder. Clin Psychiatry. 2010;71(9):1176-1186, quiz 1252-1253.
35. Arvilommi P, Suominen K, Mantere O, et al. Maintenance treatment received by patients with bipolar I and II disorders-a naturalistic prospective study. J Affect Disord. 2010;121(1-2):116-126.
36. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33, quiz 34-57.
37. Licht RW. Lithium: still a major option in the management of bipolar disorder. CNSNeurosci Ther. 2012;18(3):219-226.
38. Nivoli AM, Murru A, Vieta E. Lithium: still a cornerstone in the long-term treatment in bipolar disorder? Neuropsychobiology. 2010;62(1):27-35.
39. Geddes JR, Burgess S, Hawton K, et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry. 2004;161(2):217-222.
40. Calabrese JR, Vieta E, El-Mallakh R, et al. Mood state at study entry as predictor of the polarity of relapse in bipolar disorder. Biol Psychiatry. 2004;56(12):957-963.
41. Vieta E, Berk M, Wang W, et al. Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients. J Affect Disord. 2009;119(1-3):22-27.
42. Popovic D, Reinares M, Goikolea JM, et al. Polarity index-of pharmacological agents used for maintenance treatment of bipolar disorder. Eur Neuropsychopharmacol. 2012;22(5):339-346.